Related Experiment Videos

[Forlax in the treatment of childhood constipation: a randomized, controlled, multicenter clinical study]

Bao-Xi Wang1, Mao-Gui Wang, Mi-Zu Jiang

  • 1Department of Pediatrics, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China. erkewbx@fmmu.edu.cn

Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics
|October 17, 2007
PubMed

Insights

Polyethylene glycol 4000 (Forlax) effectively treats constipation in children over 8 years old. This randomized trial showed Forlax improved bowel movements and relieved abdominal pain more than lactulose, with no serious side effects.

Area of Science:

  • Pediatric Gastroenterology
  • Pharmacology
  • Clinical Trials

Background:

  • Constipation is a common gastrointestinal issue in children.
  • Effective and safe treatment options are crucial for pediatric patients.

Purpose of the Study:

  • To evaluate the therapeutic efficacy and safety of polyethylene glycol 4000 (Forlax) for treating constipation in children aged 8 years and older.

Main Methods:

  • A randomized, multicenter trial comparing Forlax (20 g/d) to lactulose (15 mL/d) for 2 weeks in 216 children with constipation.
  • Outcomes assessed included bowel movement frequency, stool consistency, clinical remission rates, and abdominal symptoms.

Main Results:

  • Forlax significantly increased bowel movement frequency and improved stool consistency compared to lactulose.
  • The clinical complete remission rate for constipation was higher with Forlax (72%) versus lactulose (41%) by week 2.
  • Abdominal pain resolved in 75% of patients on Forlax, compared to 57% on lactulose.

Conclusions:

  • Polyethylene glycol 4000 (Forlax) demonstrates significant safety and effectiveness in treating constipation in children over 8 years old.
  • Forlax offers a superior treatment option for pediatric constipation, showing better efficacy in symptom resolution and remission rates.
Abstract

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...